Trials / Completed
CompletedNCT04311177
Losartan for Patients With COVID-19 Not Requiring Hospitalization
Randomized Controlled Trial of Losartan for Patients With COVID-19 Not Requiring Hospitalization
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 117 (actual)
- Sponsor
- University of Minnesota · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center, double-blinded study of COVID-19 infected patients randomized 1:1 to daily losartan or placebo for 10 days or treatment failure (hospital admission).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Losartan | Losartan; 25 mg daily; oral administration |
| OTHER | Placebo | Placebo (microcrystalline methylcellulose, gelatin capsule); oral administration |
Timeline
- Start date
- 2020-04-09
- Primary completion
- 2021-02-01
- Completion
- 2021-02-01
- First posted
- 2020-03-17
- Last updated
- 2022-05-04
- Results posted
- 2022-05-04
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04311177. Inclusion in this directory is not an endorsement.